About: LTB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: LTB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	LTB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects
Creator	Andersson, Morgan Greiff, Lennart Widegren, Henrik Johnston, Sebastian Borgeat, Pierre Flamand, Louis
Source	Elsevier; Medline; PMC
abstract	Summary Background Leukotriene B4 (LTB4) recruits and activates neutrophils. Accordingly, this leukotriene is involved in innate defense actions. Objective To examine if nasal LTB4 can produce neutrophil activity and to explore whether or not LTB4 can condition neutrophils to exert virucidal effects in vitro and in vivo. Methods 1. Twenty-three healthy subjects received nasal LTB4 in a randomized and sham-controlled design. Symptoms were scored and nasal lavages carried out. Myeloperoxidase (MPO) and α-defensins were monitored as indices of neutrophil activity. IL-8, eosinophil cationic protein (ECP) and α2-macroglobulin were measured as indices of pro-inflammatory cytokine production, eosinophil activity, and plasma exudation. 2. Supernatants from neutrophils activated by LTB4 in vitro were assayed for virucidal activity against respiratory viruses. 3. In 38 healthy individuals, nasal inoculation with human rhinovirus-16 (HRV-16) was performed. In a preliminary study, intervention with LTB4 was given in a randomized and controlled design. Symptoms, virus replication, and antibody-titres were monitored. Results 1. LTB4 produced statistically significant increases in MPO and α-defensins, whereas IL-8, ECP, and α2-macroglobulin were unaffected. 2. The supernatants efficiently killed human coronavirus, respiratory syncytial virus, and influenza B virus. 3. HRV-16 replication was lower in subjects receiving LTB4, but this difference failed to reach statistical significance. Common cold symptoms and incidence of seroconversion were unaffected. Conclusion Nasal LTB4 induces a selective recruitment/activation of neutrophils. LTB4 can condition neutrophils to exert virucidal effects in vitro and may reduce virus replication in vivo. We suggest that the condition induced by LTB4 reflects an enhanced state of innate defense.
has issue date	2011-07-31(xsd:dateTime)
bibo:doi	10.1016/j.rmed.2010.12.021
bibo:pmid	21251805
has license	els-covid
sha1sum (hex)	0412a2755f49a3f0f7d7d13297b852b356a846d5
schema:url	https://doi.org/10.1016/j.rmed.2010.12.021
resource representing a document's title	LTB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects
has PubMed Central identifier	PMC7127613
has PubMed identifier	21251805
schema:publication	Respiratory Medicine
resource representing a document's body	covid:0412a2755f49a3f0f7d7d13297b852b356a846d5#body_text
is schema:about of	named entity 'NASAL' named entity 'MATTER' named entity 'H O' named entity 'I E' named entity 'L H' named entity 'N A' named entity 'ACTIVITY' named entity 'EFFECTS' named entity 'RESPIRATORY MEDICINE' named entity 'R M' named entity 'C O' named entity 'D I' named entity '6111' named entity 'L S' named entity 'NEUTROPHILS' named entity 'ANTIVIRAL' named entity 'INCREASES' named entity 'EXERT' named entity 'LTB4' named entity 'V A' named entity 'CONDITIONS' named entity 'NEUTROPHIL' named entity '105' named entity 'A T' named entity 'Respiratory Medicine' named entity 'neutrophils' named entity 'neutrophil' named entity 'neutrophils' named entity 'antiviral' named entity '2011' named entity 'leukotriene' named entity 'common cold' named entity 'sodium hydroxide' named entity 'inflammation' named entity 'defensins' named entity 'LTB4' named entity 'informed consent' named entity 'neutrophils' named entity 'neutrophil' named entity 'statistical significance' named entity 'dwell time' named entity 'human respiratory syncytial virus' named entity 'seroconversion' named entity 'allergen' named entity 'viruses' named entity 'surrogate marker' named entity '2.0' named entity 'HRV' named entity 'LTB4' named entity 'neutrophils' named entity 'placebo' named entity 'extravasation' named entity 'isotonic saline' named entity 'RSV' named entity 'intravenous administration' named entity 'cationic' named entity 'PMN' named entity 'neutrophils' named entity 'viral shedding' named entity 'viral replication' named entity 'LTB4' named entity 'f. prior' named entity 'topical administration' named entity 'defensins' named entity 'nasal cavity' named entity 'radioimmunoassay' named entity 'Supernatants' named entity 'neutrophils' named entity 'nasal mucosa' named entity 'control group' named entity 'LTB4' named entity 'viruses' named entity 'seroconversion' named entity 'eosinophils' named entity 'common cold' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software